Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire

AIDS

Volumn 17, Issue SUPPL. 3, 2003, Pages

  Djomand, Gaston ^a,f   Roels, Thierry ^a,c   Ellerbrock, Tedd ^b   Hanson, Debra ^c   Diomande, Fabien ^a   Monga, Bondo ^a   Maurice, Chantal ^a   Nkengasong, John ^a,c   Konan Koko, Regina ^d   Kadio, Auguste ^d   Wiktor, Stefan ^b   Lackritz, Eve ^b   Saba, Joseph ^e   Chorba, Terence ^a,b  

^a Project RETRO CI Abidjan   (Côte d’Ivoire)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^e UNAIDS   (Switzerland)

^f Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Africa; AIDS; Antiretroviral treatment; C te d'Ivoire; Highly active antiretroviral therapy; HIV infection

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AFRICA; ARTICLE; BLOOD TOXICITY; CELLULAR IMMUNITY; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COTE D'IVOIRE; DRUG EFFECT; EVALUATION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEPHROTOXICITY; PANCREAS DISEASE; PATIENT CARE; PATIENT EDUCATION; PATIENT SELECTION; PRIORITY JOURNAL; SCREENING; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0042354679     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200317003-00002     Document Type: Article

References (26)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency infection. N Engl J Med 1998; 338:1933-1942.
2. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients with human immunodeficiency infection. Lancet 1998; 352:1725-1730.
3. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999; 13:1933-1942.
4. Adler MW. Antiretrovirals for developing world. Lancet 1998; 351:232-233.
5. Gilks CF, Katabira E, DeCock KM. The challenge of providing effective care for HIV/AIDS in Africa. AIDS 1997; 11(suppl B):S99-S106.
6. Colebunders R, Karita E, Taelman H, Mugyenyi P. Antiretroviral treatment in Africa. AIDS 1997; 11(suppl B):S107-S113.
7. Farmer P, Leandre F, Mukherjee JS, Claude M, Nevil P, Smith-Fawzi MC, et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet 2001; 358: 404-410.
8. UNAIDS. Access to drugs. UNAIDS Technical Update. In: UNAIDS Best Practice Collection. Geneva: UNAIDS; October, 1998.
9. National Institute of Allergy and Infectious Diseases, Division of AIDS. Table for Grading Severity of Adult Adverse Experiences. Bethesda, MD: National Institute of Allergy and Infectious Diseases;, August 1992.
10. Nkengasong JN, Maurice C, Koblavi S, Kalou M, Yavo D, Maran M, et al. Evaluation of HIV serial and parallel serologic testing algorithms in Abidjan, Côte d'Ivoire. AIDS 1999; 13:109-117.
11. Nkengasong JN, Maurice C, Koblavi S, Kalou M, Bile C, Yavo D, et al. Field evaluation of a combination of monospecific enzyme-linked immunosorbent assays for type-specific diagnosis of human immunodeficiency virus type 1 (HIV-1) and HIV-2 infections in HIV-seropositive persons in Abidjan, Ivory Coast. J Clin Microbiol 1998; 36:123-127.
12. Nkengasong JN, Kalou M, Maurice C, Bile C, Borget MY, Koblavi S, et al. Comparison of NucliSens and Amplicor monitor assays for quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma of persons with HIV-1 subtype A infection in Abidjan, Cote d'Ivoire. J Clin Microbiol 1998; 36:2495-2498.
13. Ellenberger DL, Pieniazek D, Nkengasong J, Luo CC, Devare S, Maurice C, et al. Genetic analysis of human immunodeficiency virus in Abidjan, Ivory Coast reveals predominance of HIV type 1 subtype A and introduction of subtype G. AIDS Res Hum Retroviruses 1999; 15:3-9.
14. Friedman JH. A Variable Span Smoother. Technical Report 5., Stanford, CA: Laboratory for Computational Statistics, Department of Statistics, Stanford University; 1994.
15. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73:13-22.
16. Gentleman R, Geyer CJ. Maximum likelihood for interval censored data: consistency and computation. Biometrika 1994; 81:618-623.
17. Collett D. Modelling Survival Data in Medical Research. London: Chapman and Hall; 1994.
18. Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41(no. RR-17):1-19.
19. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults. JAMA 2001; 285:1155-1163.
20. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001; 15:1369-1377.
21. Montaner JSG, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized, double blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. JAMA 1998; 279:930-937.
22. Taegtmeyer M, Chebet K. Overcoming challenges to the implementation of antiretroviral therapy in Kenya. Lancet Infect Dis 2002; 2:51-33.
23. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002; 360:34-40.
24. Binswanger HP. HIV/AIDS Treatment for millions. Science 2001; 292:221-223.
25. The Global Fund to Fight AIDS, Tuberculosis and Malaria. The Global Fund to Fight AIDS, Tuberculosis and Malaria announces first grants: commits up to $616 million over two years for prevention and treatment. Available at http://www.globalfundatm.org/journalists/journalists_pr.html. Accessed on May 8, 2002.
26. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. April 2002. Available at http://www.who.int/HIV_AIDS/HIV_AIDS_Care/ARV_Draft_April_2002.pdf. Accessed on May 8, 2002.